July 2023 in “Clinical Cosmetic and Investigational Dermatology” In this case report, a 64-year-old Thai woman with a history of misdiagnosed eczema or folliculitis was ultimately found to have granular parakeratosis of the eccrine ostium, leading to significant symptom improvement once accurately diagnosed and advised to avoid excessive heat and moisture.
June 2023 in “Frontiers in Bioengineering and Biotechnology” This review describes bioengineering strategies to mimic the natural cell microenvironment in vitro, emphasizing the novel approach of using cell-synthesized extracellular matrix as a scaffold for engineering functional 3D tissues, while highlighting the limitations of exogenous scaffolds in tissue engineering.
June 2023 in “International journal of pharmaceutical quality assurance” This study found that Eclipta alba extracts exhibit 5α-reductase inhibitory activity, with the methanolic extract showing a higher concentration of β-sitosterol compared to petroleum ether extract, indicating potential for treating androgenic conditions like male pattern baldness.
May 2023 in “Zenodo (CERN European Organization for Nuclear Research)” In this review, researchers synthesized current knowledge on Eclipta alba (Bhringaraja) from traditional Ayurvedic texts and scientific literature, reporting its wide range of pharmacological properties, including hepatoprotective, antioxidant, antimicrobial, and anticancer effects, attributed to its chemical compounds like wedelolactone.
May 2023 in “GSC Advanced Research and Reviews” This review highlights the diverse pharmacological properties of Eclipta alba, often used traditionally in Asian medicine, detailing its hepatoprotective, hair growth promoting, antidiabetic, and other therapeutic activities linked to its chemical compounds such as wedelolactone.
April 2023 in “Journal of Investigative Dermatology” This study identified ectomesenchyme as a major source of epidermal stem cells in mouse skin, with ectomesenchymal keratinocytes occupying a significant portion of the epidermal stem cell-enriched population.
This research reports that after genotoxic stress from ionizing radiation or chemotherapy, hair follicles can utilize progenitor cells from transit-amplifying compartments, not quiescent stem cells, for repair, suggesting a potential therapeutic approach to prevent therapy-induced hair loss by activating these progenitors.
This study suggests that targeting the activation of transit-amplifying cell-derived progenitor cells may help prevent hair loss from chemotherapy and radiotherapy by promoting hair follicle regeneration.
January 2023 in “Journal of cosmetic dermatology” This study found that the synthetic retinoid EC23 effectively induces keratinocyte hyperproliferation and enhances hair growth in mice, showing more potency than all-trans retinoic acid.
January 2023 in “Indian dermatology online journal” This case report describes a novel NECTIN4 gene mutation linked to ED-syndactyly syndrome 1 in a young girl, contributing to the understanding of this rare ectodermal dysplasia.
December 2022 in “Journal of Experimental Biology and Agricultural Sciences” This study found that a specific combination of plant growth regulators effectively enhanced in vitro propagation and rooting of Eclipta alba, potentially enabling commercial-scale plant production.
October 2022 in “International journal of pharmaceutical sciences review and research” This study compared the antioxidant and antidiabetic activities of Hibiscus rosa-sinensis leaf extract and Eclipta alba bark extract, finding that Hibiscus rosa-sinensis exhibited greater antidiabetic activity, whereas Eclipta alba demonstrated stronger antioxidant activity.
June 2022 in “International Journal of Science and Research (IJSR)” This article discusses the potential of Bhringraj, a plant used in Ayurvedic and Unani medicine, for its significant bioactive compounds and therapeutic applications, emphasizing the importance of its extraction processes and its demonstrated non-toxic nature in rat and mice studies at high doses.
May 2022 in “International Journal for Research in Applied Science and Engineering Technology” This study reported that Eclipta prostrata contains active phytochemicals and demonstrated antibacterial properties in methanolic extracts, suggesting potential antibiotic uses.
April 2022 in “Research Square (Research Square)” This study found that the biosynthetic pathways of coumestans in Eclipta prostrata are derived from acetate and shikimate pathways, while 3,5-di-O-caffeoylquinic acid biosynthesis originates exclusively from the shikimate pathway.
February 2022 in “Research Journal of Biotechnology” This review discusses the taxonomy, traditional uses, and pharmacological activities of the medicinal plant Eclipta alba but reports no new clinical findings.
January 2022 in “Zenodo (CERN European Organization for Nuclear Research)” This review discusses the various traditional uses and reported bioactivities of Eclipta prostrata but does not present new research findings.
This review discusses the medicinal uses and phytochemical composition of Eclipta alba and reports no new clinical findings; the authors suggest its potential therapeutic significance due to complex interactions of its constituents.
June 2021 in “Dermatology Online Journal” This case report documents the first known occurrence of alopecia areata in a patient with ectodermal dysplasia linked to a WNT10A mutation, suggesting potential shared genetic factors in hair loss pathways.
This study characterized Eclipta alba for use in a capillary product for alopecia, confirming its suitable physico-chemical properties and pharmacological constituents, including wedelolactone for hair growth.
March 2021 in “Research Square (Research Square)” This research observed that 3D electrospun micro/nanofibrous sponges, without using chemical crosslinking agents, supported enhanced cell growth, vascularization, and skin regeneration in diabetic rats compared to 2D fiber membranes, making them promising for 3D tissue regeneration.
December 2020 in “Dermatología argentina” This case report describes a patient with psoriasis who developed vesiculobullous dermatitis on the palms and soles after starting treatment with secukinumab.
December 2020 in “International Journal of Biosciences (IJB)” This review discusses a traditional medicinal plant used in various holistic health systems and reports its potential antitumor activity, but no new clinical results are provided.
July 2020 in “Research Square (Research Square)” This study found that a 3D co-culture of adipose-derived stem cells and endothelial colony forming cells restored stem cell properties and enhanced wound healing in a mouse model.
April 2020 in “Journal of the Endocrine Society” This case report describes a 34-year-old woman with pituitary stalk interruption syndrome, highlighting the need for long-term follow-up due to potential progression from isolated hormonal deficiencies to pan-hypopituitarism.
April 2020 in “Journal of the Endocrine Society” In this case study, the use of somatostatin analogues was effective in localizing and confirming a neuroendocrine lung tumor as the source of ectopic ACTH syndrome, leading to marked clinical improvement in a patient unable to undergo surgery.
January 2020 in “Ayurline: IJ-RIM” This study found that Eclipta alba Hassk. (Bhrungraj) significantly inhibited the growth of human liver cancer cells, suggesting its potential as an anticancer agent.
January 2020 in “Journal of Medicinal Plants Studies” This review highlights advancements in the cultivation and chemical analysis of Eclipta alba (L.) Hassk., including increased bioactive compounds in induced tetraploids and successful micropropagation techniques, supporting its medicinal use and production efficiency.
September 2019 in “The journal of investigative dermatology/Journal of investigative dermatology” This study identifies two previously unreported pathogenic RIPK4 gene variants, suggesting a functional link with cell adhesion molecules in ectodermal dysplasias.
September 2019 in “Journal of Investigative Dermatology” In this study, dose-response modeling predicted that once-daily abrocitinib doses of 100 mg and 200 mg may provide a clinically meaningful response in treating moderate-to-severe atopic dermatitis compared to placebo.